ARZEDA CORP

AI/ML relevance scores 7 because computational design of enzymes inherently relies on machine learning (protein structure prediction, generative models, molecular simulations), but the award description frames this as an enzymatic therapeutics problem rather than explicitly naming the AI/ML methods or deliverables. Problem framing scores 5 — this is exceptionally well-articulated: a specific, high-stakes operational problem (medical countermeasures to nerve agents), clear end-user (DoD/warfighter), and implicit success criteria (efficacy and stability of prophylactics/therapeutics). Awardee quality scores 4: Arzeda Corp is a biotech startup (synthetic biology, computational protein design) rather than a legacy prime, but it is not a pure AI company — it is a domain-native biotech firm applying AI/ML as a core tool, which is appropriate but not 'AI-native defense' in the narrow sense.